The terms, per the grant. On January 21, 2020, Sanofi was issued US10538567B2, "Compounds as peptidic trigonal GLP1/glucagon/GIP receptor agonists." The CPC tags — C07K 14/57563 and C07K 14/605 (the glucagon/GLP-1 peptide families), plus A61K 38/2278 — place it squarely in the engineered-incretin-peptide stack that now anchors the most valuable franchise in therapeutics.

Why a business desk flags a 2020 grant in 2026: the multi-receptor peptide — a single molecule agonizing GLP-1, glucagon, and GIP receptors — is the structural idea behind the tri-agonist programs now commanding premium valuations and licensing interest. The point is not that this specific molecule won; the point is that the date stamp shows the thesis was real and protected before the market priced it.

“The present invention relates to trigonal GLP-1/glucagon/GIP receptor agonists and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as for reduction of excess food intake.”— U.S. Patent No. 10,538,567 source

The disciplined read for a model: issued composition-of-matter peptide claims are the bankable assets in metabolic drugs, not the platform narrative. A grant on a peptide family is the kind of asset that underwrites an upfront payment, a milestone schedule, or a defense against an early follow-on. Naming the grant by number is how you separate a real estate from a press-release pipeline.

What the document does not say: it does not promise clinical superiority over a dual agonist, it does not clear freedom to operate around competing peptide estates, and it does not guarantee the molecule reaches a label. Those are separate facts in separate records — a grant is an exclusivity claim on a structure, not a verdict on the medicine.

The takeaway for anyone valuing the GLP-1 lane: count the issued peptide grants by priority date and read what each independent claim actually recites. Sanofi's tri-agonist grant is a concrete, dated brick from early 2020 — evidence that the arms race over multi-receptor metabolic peptides was being fought in the patent office well before it reached the earnings calls.